Emotional, Psychological, and Social Well-being Experience of Long-Term Living with Type 1 Diabetes Mellitus: A Patient–Psychiatrist–Endocrinologist Perspective
AbstractType 1 diabetes mellitus (T1DM) is a chronic autoimmune disease that impacts blood glucose levels and can also lead to an increased prevalence of psychiatric conditions. Living with T1DM has been associated with a significant impact on a person’s social, mental, and psychological quality of life (QoL ). Stressors related to T1DM include the demands of managing the condition, acceptance of the diagnosis, and recognition of the sizeable personal responsibility involved in managing the condition. Participating in treatment designed to improve QoL can still take a psychological toll on individuals w ith T1DM and ca...
Source: Diabetes Therapy - January 17, 2024 Category: Endocrinology Source Type: research
Impact of Living with Stigma in Persons with Type 1 Diabetes: A Patient –Physician Perspective
AbstractType 1 diabetes mellitus (T1D) is an autoimmune disorder characterized by a complete deficiency in insulin due to the destruction of pancreatic beta cells. Globally, T1D accounts for nearly 5 –10% of the total diabetes cases. Living with this life-long condition has a significant emotional, psychological, physical, mental, and social impact. Despite extensive research characterizing the underlying physiology of T1D, additional work is needed to address the psychosocial aspects associat ed with the condition and its effect on the quality of life (QoL) of people living with T1D. One area that warrants further explo...
Source: Diabetes Therapy - January 16, 2024 Category: Endocrinology Source Type: research
A Podcast on the Use of CGM in Optimizing Type 2 Diabetes Management with Non-intensive Insulin Treatment in the Primary Care Setting
ConclusionThe podcast “The use of CGM in optimizing type 2 diabetes management with non-intensive insulin treatment in the primary care setting” highlights the transformative potential of CGM in type 2 diabetes care. It encourages patients and healthcare providers to consider CGM as an integral part of treatment plan s, ultimately improving the lives of those living with type 2 diabetes.Podcast Video (MP4 261831 KB) (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 13, 2024 Category: Endocrinology Source Type: research
A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
ConclusionOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.Trial RegistrationjRCTs2051190029 and NCT04018365. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 13, 2024 Category: Endocrinology Source Type: research
A Podcast on the Use of CGM in Optimizing Type 2 Diabetes Management with Non-intensive Insulin Treatment in the Primary Care Setting
ConclusionThe podcast “The use of CGM in optimizing type 2 diabetes management with non-intensive insulin treatment in the primary care setting” highlights the transformative potential of CGM in type 2 diabetes care. It encourages patients and healthcare providers to consider CGM as an integral part of treatment plan s, ultimately improving the lives of those living with type 2 diabetes.Podcast Video (MP4 261831 KB) (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 13, 2024 Category: Endocrinology Source Type: research
A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
ConclusionOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.Trial RegistrationjRCTs2051190029 and NCT04018365. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 13, 2024 Category: Endocrinology Source Type: research
A Systematic Literature Review of Psychological Interventions for Adults with Type 1 Diabetes
DiscussionCurrent guidelines for the treatment of T1DM recommend access to psychological services; however, there is a paucity of high-quality evidence from clinical trials on the effectiveness or preferred structure of psychological support. There is a clear need for more rigorous, large-scale, international research to address the efficacy of psychological interventions in ALWT1DM. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 6, 2024 Category: Endocrinology Source Type: research
The Effect of Sodium –Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials
ConclusionOur findings suggest that adjunctive therapy with SGLT inhibitors results in a significant reduction in albuminuria, while their use is associated with a neutral effect on creatinine clearance, as a measure of renal function. Future renal outcome trials are needed to assess SGLT inhibitors ’ role in the pharmacological armamentarium against diabetic nephropathy in T1D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 5, 2024 Category: Endocrinology Source Type: research
Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies
ConclusionsThis review consolidates the positive current evidence base for prescribing semaglutide to patients with T2DM, but further rigorous studies are still urgently required to develop practice guidelines as innovative drugs become commercially available. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 4, 2024 Category: Endocrinology Source Type: research
Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production
ConclusionsIn patients with T2D-CAD, beneficial effects of dapagliflozin on coronary microcirculation seem to be unrelated to HDL functions. However, HDL capacity to stimulate NO production is not impaired at baseline; thus, the effect of drug treatments would be negligible. To conclude, we can assume that HDL-independent molecular pathways are involved in the improvement of MFR in this population.Trial RegistrationEudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 1, 2024 Category: Endocrinology Source Type: research
